Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
43 studies found for:    MACULAR DYSTROPHY, RETINAL, 3
Show Display Options
Rank Status Study
1 Recruiting Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular Age-related Macular Degeneration
Conditions: Exudative Macular Degeneration;   Retinal Hemorrhage
Interventions: Drug: Ranibizumab;   Drug: C3F8 Gas;   Drug: tPA
2 Active, not recruiting Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration
Condition: Macular Degeneration
Intervention: Dietary Supplement: Omega-3 fatty acid
3 Recruiting Omega 6:Omega 3 Ratio and Progression of Age-related Macular Degeneration (AMD).
Condition: Age-related Macular Degeneration
Intervention:
4 Active, not recruiting Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)
Condition: Age-related Macular Degeneration
Interventions: Drug: Omega-3 fatty acids (fish oil);   Dietary Supplement: Vitamin D3;   Dietary Supplement: Vitamin D3 placebo;   Dietary Supplement: Fish oil placebo
5 Completed Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
Condition: Age-Related Macular Degeneration
Intervention: Drug: pegaptanib sodium (Macugen)
6 Not yet recruiting Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: NT-503-3 ECT implantation;   Drug: Eylea® injected intravitreally administered every 8 weeks
7 Completed Omega-3-fatty Acids on Age-related Macular
Condition: Aged Macular Degeneration
Interventions: Dietary Supplement: Omega 3;   Other: Olive Oil
8 Completed Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD
Condition: Macular Degeneration
Interventions: Drug: Anecortave Acetate 15 mg sterile suspension;   Other: Photodynamic Therapy (PDT)
9 Recruiting A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030;   Drug: ranibizumab;   Drug: E10030 sham intravitreal injection
10 Recruiting A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030;   Drug: ranibizumab;   Drug: E10030 sham intravitreal injection
11 Recruiting A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
Condition: Age-Related Macular Degeneration
Interventions: Drug: E10030;   Drug: bevacizumab  or  aflibercept;   Drug: E10030 sham intravitreal injection
12 Completed Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60
Condition: Macular Degeneration
Intervention: Drug: Lutein
13 Completed Consumption of Eggs Rich in Lutein and Omega-3 Fatty Acids on the Macular Pigment
Condition: Age-related Macular Degeneration
Intervention: Other: Nutritional study
14 Completed
Has Results
A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema
Conditions: Macular Edema;   Diabetic Mellitus;   Retinal Disease
Interventions: Drug: pegaptanib sodium;   Other: sham injection
15 Completed
Has Results
Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD
Condition: Exudative Age-related Macular Degeneration.
Interventions: Dietary Supplement: Anti-VEGF plus AREDS-2;   Dietary Supplement: Anti-VEGF plus AREDS-1
16 Completed Aqueous Vascular Endothelial Growth Factor (VEGF) Levels in Type 3 Neovascularization
Condition: Age-related Macular Degeneration
Intervention: Procedure: Aqueous sample
17 Completed
Has Results
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: Ranibizumab;   Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
18 Completed A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD
Condition: Neovascular Age-related Macular Degeneration
Intervention: Biological: Recombinant Human VEGF Receptor-Fc Fusion Protein
19 Completed Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: Palomid 529
20 Unknown  Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: ORA102 and Avastin;   Drug: Avastin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years